Last updated: 2026-11-13 13:01:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
United Therapeutics Corp. (UTHR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $595.95, with a market capitalization of $25.27B and a P/E ratio of 20.53. Over the past 52 weeks, its price has ranged from $455.63 to $624.31. This page covers its latest market performance, valuation, price trends and company information.
$25.27B | |
$589.18 | |
$624.31 | |
$589.18 | |
$593.31 | |
6.00 | |
700.19K | |
20.53 | |
$624.31 | |
$455.63 | |
-- | |
-- |
United Therapeutics Corp. (UTHR) is trading at $595.95 in pre-market trading as of 2026-11-13 12:54:00, up 0.44% ($2.64) from the previous close of $593.31
Pre-market trading shows how investors are pricing UTHR before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, United Therapeutics Corp. (UTHR) moved from $565.72 to $595.95, representing a gain of 5.34% ($30.23).
The stock traded between $556.63 and $624.31 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 404.27 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 83.2%
UTHR is currently trading at $595.95, placing it 83.2% of the way from its 52-week low of $455.63 to its 52-week high of $624.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 1,400 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to United Therapeutics Corp. and UTHR stock.
United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 15 years by 6.56% on an annualized basis producing an average annual return of 19.5%. Currently, United Therapeutics has a market
Liquidia Corporation (LQDA) reported strong Q3 2026 results with earnings of 80 cents per share and revenues of $225.3 million, driven by Yutrepia sales of $222.7 million. However, a $389.7 million litigation settlement with United Therapeutics restricts Yutrepia's promotion to pulmonary arterial hypertension only, eliminating PH-ILD commercialization. The company maintains confidence in PAH growth and has sufficient cash reserves to support settlement payments and pipeline expansion.
Liquidia Corporation (LQDA) reported Q3 2026 revenues of $225.3M, surging 314.6% year-over-year, with YUTREPIA sales reaching $222.7M, up 31% sequentially. The company achieved record October patient shipments and expanded its prescriber base to 1,300 despite temporary referral disruptions following a settlement with United Therapeutics. Management maintained a 94% gross margin and plans to provide 2027 revenue guidance in January.
Eligible investors can buy real shares of United Therapeutics Corp. (UTHR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to UTHR, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between UTHR shares and USD.
UTHR Shares to USD
1.00 UTHR shares = 595.946 USD
Calculations are estimates based on the latest available price and are for reference only.
